Stereotaxis, Inc.

Equities

STXS

US85916J4094

Advanced Medical Equipment & Technology

Market Closed - Nyse Other stock markets 04:00:00 2024-07-02 pm EDT			5-day change	1st Jan Change
1.76 ^USD	-0.56%		+0.57%	+0.57%

May. 29	Stereotaxis' Robotic Navigation System Used to Treat First Patients	MT
May. 29	Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System	CI

Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024

May 13, 2024 at 04:03 pm EDT

Stereotaxis, Inc. provided revenue guidance for the full year 2024. For the year, the company expects maintains its expectation of double-digit revenue growth for the full year 2024 driven by revenue recognition of system backlog and new system orders, and not incorporating contribution of revenue from APT.

Latest news about Stereotaxis, Inc.

Stereotaxis' Robotic Navigation System Used to Treat First Patients	May. 29	MT
Stereotaxis, Inc. Announces the Successful Treatment of the First Heart Rhythm Patients by Penn Presbyterian Medical Center Utilizing the Advanced Genesis Robotic Magnetic Navigation System	May. 29	CI
Stereotaxis Receives CE Mark Recertification in EU	May. 24	MT
Transcript : Stereotaxis, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Stereotaxis to Buy Access Point Technologies	May. 13	MT
Earnings Flash (STXS) STEREOTAXIS Reports Q1 Revenue $6.9M, vs. Street Est of $7.1M	May. 13	MT
Stereotaxis, Inc. Provides Revenue Guidance for the Full Year 2024	May. 13	CI
Stereotaxis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
Stereotaxis, Inc. entered into a definitive share purchase agreement to acquire Access Point Technologies, Inc. for $3 million.	May. 12	CI
Transcript : Stereotaxis, Inc., Q4 2023 Earnings Call, Mar 04, 2024	Mar. 04
Earnings Flash (STXS) STEREOTAXIS Reports Q4 Revenue $4.6M, vs. Street Est of $7.7M	Mar. 04	MT
Stereotaxis, Inc. Announces Regulatory Submissions of the MAGiC Ablation Catheter in Europe and the United States	Mar. 04	CI
Stereotaxis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 04	CI
Stereotaxis, Inc. Provides Revenue Guidance for the First Quarter and Full Year 2024	Mar. 04	CI
North American Morning Briefing : Stock Futures -2-	Mar. 04	DJ
Roth MKM Starts Coverage on Stereotaxis with Buy Rating, $5 Price Target	Jan. 10	MT
Stereotaxis Announces First Patients Successfully Treated Using Magic Ablation Catheter	Jan. 08	CI
B. Riley Trims Stereotaxis' PT to $4 From $4.50 After Slight Q3 Miss, Maintains Buy Rating	Nov. 10	MT
Transcript : Stereotaxis, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Stereotaxis, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (STXS) STEREOTAXIS Posts Q3 Revenue $7.8M, vs. Street Est of $8.3M	Nov. 09	MT
Stereotaxis Says First US Arrhythmia Patients Treated with Robotic Navigation and Abbott's Cardiac Mapping System	23-10-31	MT
Stereotaxis Launches and Successfully Completes the First Procedures Using the Advanced Genesis Robotic Magnetic Navigation System	23-08-30	CI
Transcript : Stereotaxis, Inc., Q2 2023 Earnings Call, Aug 10, 2023	23-08-10
Earnings Flash (STXS) STEREOTAXIS Reports Q2 Revenue $7.9M, vs. Street Est of $6.7M	23-08-10	MT

Chart Stereotaxis, Inc.

Duration

Period

More charts

Company Profile

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments and information systems for the interventional laboratory. Its proprietary robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. The Companyâs primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. Through its strategic relationships with fluoroscopy system manufacturers, providers of catheters and electrophysiology mapping systems, and other parties, the Company offers its customers x-ray systems and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.76 USD

Average target price

4.5 USD

Spread / Average Target

+155.68%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
STEREOTAXIS, INC.	+0.57%	145M
THERMO FISHER SCIENTIFIC	+0.59%	204B
DANAHER CORPORATION	+3.92%	178B
INTUITIVE SURGICAL, INC.	+30.07%	156B
BOSTON SCIENTIFIC CORPORATION	+32.42%	113B
SIEMENS HEALTHINEERS AG	+1.63%	64.26B
EDWARDS LIFESCIENCES CORPORATION	+19.65%	54.98B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.86%	47.44B
AGILENT TECHNOLOGIES, INC.	-9.53%	36.7B
GE HEALTHCARE TECHNOLOGIES INC.	-1.28%	34.84B

Other Advanced Medical Equipment & Technology